342 related articles for article (PubMed ID: 18201271)
1. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
Yokouchi H; Yamazaki K; Chamoto K; Kikuchi E; Shinagawa N; Oizumi S; Hommura F; Nishimura T; Nishimura M
Cancer Sci; 2008 Feb; 99(2):361-7. PubMed ID: 18201271
[TBL] [Abstract][Full Text] [Related]
2. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
[TBL] [Abstract][Full Text] [Related]
4. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
5. Combination immunotherapy with radiation and CpG-based tumor vaccination for the eradication of radio- and immuno-resistant lung carcinoma cells.
Chamoto K; Takeshima T; Wakita D; Ohkuri T; Ashino S; Omatsu T; Shirato H; Kitamura H; Togashi Y; Nishimura T
Cancer Sci; 2009 May; 100(5):934-9. PubMed ID: 19245434
[TBL] [Abstract][Full Text] [Related]
6. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
[TBL] [Abstract][Full Text] [Related]
7. Intravenous administration of MIP-1alpha with intra-tumor injection of P. acnes shows potent anti-tumor effect.
Nakano A; Yoneyama H; Ueha S; Kitabatake M; Ishikawa S; Kawase I; Sugiyama H; Matsushima K
Int Immunopharmacol; 2007 Jun; 7(6):845-57. PubMed ID: 17466918
[TBL] [Abstract][Full Text] [Related]
8. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effect of pEgr-interferon-gamma-endostatin gene-radiotherapy in mice bearing Lewis lung carcinoma and its mechanism.
Yang W; Li XY
Chin Med J (Engl); 2005 Feb; 118(4):296-301. PubMed ID: 15740667
[TBL] [Abstract][Full Text] [Related]
10. Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies.
Gray JC; French RR; James S; Al-Shamkhani A; Johnson PW; Glennie MJ
Eur J Immunol; 2008 Sep; 38(9):2499-511. PubMed ID: 18792403
[TBL] [Abstract][Full Text] [Related]
11. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
Weinberg AD; Thalhofer C; Morris N; Walker JM; Seiss D; Wong S; Axthelm MK; Picker LJ; Urba WJ
J Immunother; 2006; 29(6):575-85. PubMed ID: 17063120
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study for the targeting therapy of mouse lung carcinoma treated by anti-hnRNPB1 monoclonal antibody with 131I].
Chen MY; Li WM; Xu D; Chen WB
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):766-9. PubMed ID: 17953353
[TBL] [Abstract][Full Text] [Related]
13. Increase in efficacy of cancer radiotherapy by combination with whole-body low dose irradiation.
Wu N; Jin SZ; Pan XN; Liu SZ
Int J Radiat Biol; 2008 Mar; 84(3):201-10. PubMed ID: 18300020
[TBL] [Abstract][Full Text] [Related]
14. Combined IFN-gamma-endostatin gene therapy and radiotherapy attenuates primary breast tumor growth and lung metastases via enhanced CTL and NK cell activation and attenuated tumor angiogenesis in a murine model.
Liu LL; Smith MJ; Sun BS; Wang GJ; Redmond HP; Wang JH
Ann Surg Oncol; 2009 May; 16(5):1403-11. PubMed ID: 19263173
[TBL] [Abstract][Full Text] [Related]
15. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
16. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
Shi W; Siemann DW
Anticancer Res; 2006; 26(5A):3445-53. PubMed ID: 17094465
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with viable human umbilical vein endothelial cells prevents metastatic tumors by attack on tumor vasculature with both cellular and humoral immunity.
Chen XY; Zhang W; Zhang W; Wu S; Bi F; Su YJ; Tan XY; Liu JN; Zhang J
Clin Cancer Res; 2006 Oct; 12(19):5834-40. PubMed ID: 17020991
[TBL] [Abstract][Full Text] [Related]
18. Introduction of OX40 ligand into lymphoma cells elicits anti-lymphoma immunity in vivo.
Kaneko H; Hori T; Yanagita S; Kadowaki N; Uchiyama T
Exp Hematol; 2005 Mar; 33(3):336-43. PubMed ID: 15730857
[TBL] [Abstract][Full Text] [Related]
19. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
20. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.
Song A; Song J; Tang X; Croft M
Eur J Immunol; 2007 May; 37(5):1224-32. PubMed ID: 17429847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
